L-Nutra Marks 10th Anniversary of Prolon® With a Milestone Year: 136 Patents, 40+ Clinical Trials, and a Series D Investment Round

A leading pioneer in longevity nutrition and one of the most clinically studied companies in the category reflects on a decade of nutri-technology firsts

LOS ANGELES, Sept. 24, 2026 /PRNewswire/ -- L-Nutra Inc., a leading pioneer in longevity nutrition and nutrition as medicine, today marked the tenth anniversary of Prolon^®, its clinically studied Fasting Mimicking Diet (FMD). The company's mission has been the same since day one: give people the chance to live 100 healthy years. A decade of scientific firsts and global growth has made L-Nutra's body of longevity research unmatched in the category.

In two recent human trials, Prolon^® became the first nutrition program shown to induce autophagy - the cellular renewal process whose discovery earned the 2016 Nobel Prize in Physiology or Medicine - and to reverse biological age by an average of 2.5 years after three consecutive cycles, a critical milestone in extending healthspan.

No other company matches L-Nutra and Prolon^®'s longevity science. The company holds:

• 136 patents in longevity and disease remission, more than any other company in the category
• 40+ completed clinical trials on its nutri-technologies
• $83.5 million raised to close a Series D round led by Mubadala Investment Company
• The #1 prescribed longevity nutrition program, trusted and recommended by more than 12,000 practitioners
• Studies conducted at 18 leading institutions, including Stanford, USC, Mayo Clinic, and Harvard, and other reputable institutions.

"Our longevity scientists, alongside researchers at 18 top global medical centers, have been conducting groundbreaking nutri-tech R&D for more than two decades under the leadership of Professor Valter Longo - one of TIME's 100 Most Influential People in Health and Director of the Longevity Institute at University of Southern California," said Dr. Joseph Antoun, CEO of L-Nutra. "We pioneered the longevity category before it became mainstream, and we're committed to turning food into a true asset for longevity and medicine - becoming the first nutrition company people turn to every day, whether they're healthy or managing an illness."

L-Nutra's science extends beyond the 5-Day FMD that built Prolon^®'s reputation. The company's nutri-technology platform now spans every day nutrition including: longevity foods, medical nutrition therapy, and precision nutrition for every life stage, all aimed at the same goal: giving people the chance to live longer in good health, not just longer.

Since Prolon^®'s introduction in 2016, the same year autophagy's mechanisms won the Nobel Prize in Physiology or Medicine, its 5-Day Fasting Mimicking Diet has been used by more than one million people to trigger autophagy, the cell's natural recycling and renewal process, and reverse biological age by an average of 2.5 years after three consecutive cycles. As L-Nutra looks to the next decade, the goal is to extend that impact to 100 million people.

L-Nutra's footprint now extends well beyond the United States, with a growing presence across Europe, Canada, and Australia, alongside its expanding work in the Middle East. Earlier this year, L-Nutra closed a Series D raise totaling $83.5 million, led by Mubadala Investment Company, one of the world's most prominent sovereign investors, fueling continued investment in research and global expansion.

"To everyone who believed in this mission from the start, and to every consumer who chose Prolon^® - thank you very much," added Dr. Antoun. "Your trust and support have helped significantly advance longevity science and the food-as-medicine movement, and in doing so, you've also helped us give back. On behalf of our community, we've been able to donate more than $1.2 million to the Create Cures Foundation, turning your support into an even bigger social impact."

About L-Nutra

L-Nutra is a leader in longevity and nutrition science, pioneering innovations that unlock the power of nutrition to support healthy aging, combat age-related conditions, and transform lives. Founded in 2009 by Professor Valter Longo, L-Nutra's research has given rise to groundbreaking fasting nutrition programs and clinically validated solutions that are reshaping the future of healthcare, employee wellness, and disease prevention. Under the leadership of Dr. Joseph Antoun, who launched the first longevity-focused investment fund in 2011 and has since helped raise more than $150 million for longevity-focused companies, L-Nutra has generated over a quarter billion dollars in sales and helped establish food as medicine as a clinically validated, commercial category. The company holds 136 patents in longevity and disease remission and has conducted 40+ clinical trials in partnership with leading research institutions including Stanford, USC, Mayo Clinic, and Harvard. Through Prolon^®, the first commercially available Fasting Mimicking Diet program, and L-Nutra Health, its healthcare division delivering 360-degree, physician-guided programs to reverse age-related disease, the company is bringing the science of longevity to the world, one cell, one person, and one organization at a time. Learn more at www.l-nutra.com.

SOURCE L-Nutra Inc.